Pfizer, BioNTech request expanded emergency use of COVID-19 vaccine in adolescents
Pfizer, BioNTech request expanded emergency use of COVID-19 vaccine in adolescents
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
(Reporting by Mrinalika Roy in Bengaluru; Editing by
Ramakrishnan M.)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;)
April 9 (Reuters) - Pfizer Inc and german partner BioNtech SE on Friday said they have requested U.S. regulatory agencies to expand the emergency use of their COVID-19 vaccine in adolescents aged 12 to 15.
In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.
The Pfizer/BioNTech two-shot vaccine is already authorized for use in people as young as 16.
(Reporting by Mrinalika Roy in Bengaluru; Editing by
Ramakrishnan M.)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;)
路透4月9日電-輝瑞(Pfizer Inc.)和德國合作伙伴BioNTech SE週五表示，他們已要求美國監管機構擴大其新冠肺炎疫苗的緊急使用範圍，適用於12至15歲的青少年。今年3月，制藥商表示，在一項臨牀試驗中，該疫苗被發現是安全、有效的，並在12至15歲的兒童中產生了強大的抗體反應。輝瑞/BioNTech雙針疫苗已經獲準在16歲以下的人羣中使用。(Mrinalika Roy在孟加盧市報道；編輯者：Ramakrishnan M.)(mrinalika.roy@thomsonreurs.com；在美國境內+1 646 2238780，美國境外+91 806749 8325；)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧